Quick Answer
Theravance Biopharma, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $107.46 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +66.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $3.09 million | Q2 2017: $3.51 million | Q3 2017: $4.28 million | Q4 2017: $4.52 million | Q1 2018: $8.32 million | Q2 2018: $23.48 million | Q3 2018: $12.84 million | Q4 2018: $15.74 million | Q1 2019: $5.34 million | Q2 2019: $26.15 million | Q3 2019: $12.43 million | Q4 2019: $29.50 million | Q1 2020: $19.86 million | Q2 2020: $15.01 million | Q3 2020: $18.26 million | Q4 2020: $18.73 million | Q1 2021: $14.26 million | Q2 2021: $12.91 million | Q3 2021: $13.19 million | Q4 2021: $14.95 million | Q1 2022: $13.20 million | Q2 2022: $11.05 million | Q3 2022: $12.45 million | Q4 2022: $14.65 million | Q1 2023: $10.42 million | Q2 2023: $13.75 million | Q3 2023: $15.69 million | Q4 2023: $17.57 million | Q1 2024: $14.50 million | Q2 2024: $14.26 million | Q3 2024: $16.87 million | Q4 2024: $18.75 million | Q1 2025: $15.39 million | Q2 2025: $26.20 million | Q3 2025: $19.99 million | Q4 2025: $45.89 million.
- Over the full 10 years of available data (2016 to 2025), Theravance Biopharma, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 120.9%.
- Historical annual values: Fiscal year 2025: $107.46 million | Fiscal year 2024: $64.38 million | Fiscal year 2023: $57.42 million | Fiscal year 2022: $51.35 million | Fiscal year 2021: $55.31 million | Fiscal year 2020: $71.86 million | Fiscal year 2019: $73.41 million | Fiscal year 2018: $60.37 million | Fiscal year 2017: $15.39 million | Fiscal year 2016: $48.65 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: